Tag:
ARCA
Latest Headlines
Latest Headlines
ARCA cardio data analysis triggers brief spike in share price
Shares of ARCA biopharma ( $ABIO ) briefly went on a tear yesterday after the Broomfield, CO-based biotech reported some impressive data based on follow-up analysis of some aging late-stage data on its
Analysts ponder soaring Arca shares
What's up at Arca Biopharma ? Analysts have been scratching their heads trying to figure out why, after the developer announced a new patent on Friday--hardly earthshattering news--its stock would go
Struggling Arca gets Nasdaq warning
Just a week after its auditors offered a going-concern red flag, Arca biopharma says that Nasdaq has issued a warning on its failure to meet the market's minimum financial threshold. The Denver
FDA fast-tracks ARCA's Gencaro
ARCA Biopharma said U.S. health regulators have granted a fast-track designation for its experimental drug, Gencaro, to treat chronic heart failure, sending its shares up as much as 81 percent. Report
Novartis, GSK meds get expanded indications
The FDA has approved Novartis' osteoporosis drug Reclast for an expanded indication. Currently approved as a once-yearly infusion to treat post-menopausal osteoporosis, the drug will now also be
ARCA shares in meltdown as FDA rejects drug
Questioning both the integrity of its late-stage data as well as its ability to demonstrate efficacy, the FDA has rejected ARCA Biopharma's heart failure drug Gencaro. The agency is demanding more
Cash-rich Nuvelo inks merger deal with ARCA
ARCA biopharma and cash-rich Nuvelo are merging in a deal that is designed to create a late-stage cardiovascular company. After the deal is complete, ARCA shareholders will own 67 percent of the
Failed heart drug effective in treating sub-pop
In a striking example of how new genetic insights can transform the drug development process, researchers announced that the heart drug bucindolol was able to reduce the risk of death for any cause
ARCA launching NDA with venture funds
Denver-based ARCA Discovery has rounded up $15 million in its first round of venture capital. The upstart already has plans to use the funds to back a New Drug Application for bucindolol, a
